Not available
Quote | Moleculin Biotech Inc. (NASDAQ:MBRX)
Last: | $4.63 |
---|---|
Change Percent: | -4.45% |
Open: | $4.5 |
Close: | $4.63 |
High: | $4.8966 |
Low: | $4.405 |
Volume: | 23,885 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Moleculin Biotech Inc. (NASDAQ:MBRX)
Moleculin CEO, Walter Klemp highlights Annamycin differentiation in the current AML treatment landscape and potential opportunity FRENCHTOWN, NJ / ACCESSWIRE / April 25, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Vir...
2024-04-18 09:13:59 ET More on Moleculin Biotech Moleculin Biotech, Inc. (MBRX) Q4 2023 Earnings Call Transcript Moleculin gets U.S. patent issue notification for annamycin targeting unmet need in AML Seeking Alpha’s Quant Rating on Moleculin Biotech H...
Message Board Posts | Moleculin Biotech Inc. (NASDAQ:MBRX)
Subject | By | Source | When |
---|---|---|---|
We all have witnessed this stock with good | TheSprinx | investorshub | 04/20/2023 3:18:19 PM |
$MBRX THIS IS GOOD >>---> As of December | TheFinalCD | investorshub | 04/19/2023 11:50:12 AM |
Recent Highlights | TheFinalCD | investorshub | 04/19/2023 11:48:28 AM |
.75 walk down on air shares this morning | TheFinalCD | investorshub | 04/19/2023 9:15:37 AM |
https://www.prnewswire.com/news-releases/moleculin-announces-presentation-of-pos | Dennisb68 | investorshub | 04/18/2023 10:47:05 PM |
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
Moleculin CEO, Walter Klemp highlights Annamycin differentiation in the current AML treatment landscape and potential opportunity FRENCHTOWN, NJ / ACCESSWIRE / April 25, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Vir...
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) PR Newswire – Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine a...
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties PR Newswire Annamycin demonstrated to be a more potent inhibitor of topoisomerase II-alpha and II-beta while remaining inactive against establi...